Recursion Pharmaceuticals vs FutureHouse
A side-by-side look at scores, pricing and features — with RECATOOLS' ASEAN-aware verdict for each.
Recursion Pharmaceuticals
Publicly traded techbio company (NASDAQ: RXRX) industrialising drug di...
Visit
|
FutureHouse
Eric-Schmidt-backed nonprofit building AI agents to automate scientifi...
Visit
|
|
|---|---|---|
| RECATOOLS Score | 7 / 10 | 7.5 / 10 |
| Capability | — | — |
| Value for money | — | — |
| Ease of use | — | — |
| ASEAN readiness | — | — |
| API quality | — | — |
| Pricing | Enterprise | Freemium |
| Free tier | — | Free public web platform and agents (Crow, Falcon, Owl, Robin) plus a free API tier for researchers. |
| Paid from | Partnership / collaboration deals (not a self-serve product) | Higher-throughput / commercial use via the Edison Scientific spinout |
| Has API | ✗ | ✓ |
| Open source | ✗ | ✗ |
| Free to use | ✗ | ✓ |
| Users | — | — |
| Founded | 2013 | 2023 |
| Maker | Chris Gibson | Sam Rodriques, Andrew White |
| Verdict | What this is for: AI-driven, industrial-scale drug discovery combining large biological datasets, automated experiments and its own supercomputing. Who this is for: Pharmaceutical and biotech partners, plus investors in... |
What this is for: Automating literature review, hypothesis generation and multi-step scientific reasoning with citation-grounded AI agents. Who this is for: Academic researchers and scientists in biology, chemistry and... |
| Full review → | Full review → |
← Back to AI Directory
Comparisons cover up to 4 tools. Scores are RECATOOLS editorial assessments; verify current pricing on each vendor's site.